Passa al contenuto
Merck

Vai a

71663

Fosfato di sodio

tested according to Ph. Eur.

Sinonimo/i:

sec-fosfato di sodio, Idrogenofosfato di disodio, Sodio fosfato bibasico

Autenticati per visualizzare i prezzi organizzativi e contrattuali.

Scegli un formato

Cambia visualizzazione
Taglio della confezioneSKUDisponibilitàPrezzo
1 kg
Per informazioni sulla disponibilità, contatta il Servizio Clienti.
103,00 €

Informazioni su questo articolo

Formula condensata:
Na2HPO4 · 12H2O
Numero CAS:
Peso molecolare:
358.14
NACRES:
NA.25
PubChem Substance ID:
UNSPSC Code:
12161700
EC Number:
231-448-7
MDL number:

103,00 €


Per informazioni sulla disponibilità, contatta il Servizio Clienti.

Richiedi un ordine in blocco
Servizio Tecnico
Hai bisogno di aiuto? Il nostro team di scienziati qualificati è a tua disposizione.
Permettici di aiutarti


agency

tested according to Ph. Eur.

Quality Level

assay

98.5-102.5%

form

crystalline

solubility

water: ~35.8 g/L at 20 °C

SMILES string

O.O.O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O

InChI

1S/2Na.H3O4P.12H2O/c;;1-5(2,3)4;;;;;;;;;;;;/h;;(H3,1,2,3,4);12*1H2/q2*+1;;;;;;;;;;;;;/p-2

InChI key

DGLRDKLJZLEJCY-UHFFFAOYSA-L

Application


  • The gelation behavior of thiolated citrus high-methoxyl pectin induced by sodium phosphate dibasic dodecahydrate.: This research explores how sodium phosphate dibasic dodecahydrate influences the gelation properties of thiolated citrus pectin, showcasing potential applications in food science and pharmaceuticals for controlled gelation processes (Chen J et al., 2022).

  • Use of cellulose nanofibril (CNF)/silver nanoparticles (AgNPs) composite in salt hydrate phase change material for efficient thermal energy storage.: Demonstrates the utility of sodium phosphate dibasic dodecahydrate in enhancing the performance of phase change materials, which are critical for energy storage systems, indicating its role in improving thermal energy storage efficiency (Shen Z et al., 2021).


Confronta articoli simili

Visualizza il confronto per intero

Mostra le differenze

1 of 1

Questo articolo
04273716491.06579
assay

98.5-102.5%

assay

98.5-102.5% (T)

assay

≥99.0% (T)

assay

99.0-102.0% (alkalimetric)

Quality Level

200

Quality Level

200

Quality Level

200

Quality Level

300

form

crystalline

form

crystals

form

crystals

form

solid

solubility

water: ~35.8 g/L at 20 °C

solubility

-

solubility

H2O: 0.1 M at 20 °C, clear, colorless

solubility

218 g/L

agency

tested according to Ph. Eur.

agency

meets analytical specifications of BP, meets analytical specifications of Ph. Eur.

agency

-

agency

reag. ISO, reag. Ph. Eur.


Still not finding the right product?

Explore all of our products under Fosfato di sodio


Classe di stoccaggio

11 - Combustible Solids

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)



Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti



Matthew H Crouthamel et al.
Arteriosclerosis, thrombosis, and vascular biology, 33(11), 2625-2632 (2013-08-24)
Elevated serum phosphate has emerged as a major risk factor for vascular calcification. The sodium-dependent phosphate cotransporter, PiT-1, was previously shown to be required for phosphate-induced osteogenic differentiation and calcification of cultured human vascular smooth muscle cells (VSMCs), but its
Matthew R Weir et al.
Journal of clinical hypertension (Greenwich, Conn.), 16(12), 875-882 (2014-10-21)
The effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure (BP) and osmotic diuresis- and intravascular volume reduction-related adverse events (AEs) were evaluated using pooled data from four placebo-controlled, phase 3 studies in patients with type 2
George G S Sandor et al.
International journal of cardiology, 179, 470-475 (2014-12-04)
Patients with Marfan (MFS) and Loeys-Dietz (LDS) syndromes have been shown to have abnormal aortic biophysical properties. The purpose of this study was to compare the effects of 12-months of therapy with atenolol or losartan on vascular function in young



Numero articolo commerciale globale

SKUGTIN
71663-1KG04061826715154

Domande

Recensioni

Nessuna valutazione

Filtri attivi